These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31960967)

  • 1. Reduction of nuclear Y654-p-β-catenin expression through SH3GL2-meditated downregulation of EGFR in chemotolerance TNBC: Clinical and prognostic importance.
    Islam MS; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Kumar Panda C
    J Cell Physiol; 2020 Nov; 235(11):8114-8128. PubMed ID: 31960967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of beta-catenin in chemo-tolerant TNBC through changes in receptor and antagonist profiles of the WNT pathway: Clinical and prognostic implications.
    Islam S; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Panda CK
    Cell Oncol (Dordr); 2020 Aug; 43(4):725-741. PubMed ID: 32430683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-catenin(Y654) are associated with breast carcinoma: Clinical and prognostic significance.
    Mukherjee N; Dasgupta H; Bhattacharya R; Pal D; Roy R; Islam S; Alam N; Biswas J; Roy A; Roychoudhury S; Panda CK
    Biochim Biophys Acta; 2016 Sep; 1862(9):1472-84. PubMed ID: 27208794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.
    Dasgupta H; Islam S; Alam N; Roy A; Roychoudhury S; Panda CK
    J Surg Oncol; 2019 Jan; 119(1):88-100. PubMed ID: 30481381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
    Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
    Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
    Maiti GP; Mondal P; Mukherjee N; Ghosh A; Ghosh S; Dey S; Chakrabarty J; Roy A; Biswas J; Roychoudhury S; Panda CK
    PLoS One; 2013; 8(5):e63440. PubMed ID: 23675485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of HRR genes and inhibition of DNMT1 is associated with anthracycline anti-tumor antibiotic-tolerant breast carcinoma cells.
    Dasgupta H; Islam MS; Alam N; Roy A; Roychoudhury S; Panda CK
    Mol Cell Biochem; 2019 Mar; 453(1-2):163-178. PubMed ID: 30178275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
    Wang W; Rana PS; Markovic V; Sossey-Alaoui K
    Breast Cancer Res; 2023 Mar; 25(1):31. PubMed ID: 36949468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RETRACTION: Reduction of Nuclear Y654-p-β-Catenin Expression Through SH3GL2-Meditated Downregulation of EGFR in Chemotolerance TNBC: Clinical and Prognostic Importance.
    J Cell Physiol; 2024 Dec; 239(12):e31485. PubMed ID: 39568308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance and mechanism of STAT3/miR-221-3p/Fascin-1 axis in EGFR TKI resistance of triple-negative breast cancer.
    Jin LL; Lu HJ; Shao JK; Wang Y; Lu SP; Huang BF; Hu GN; Jin HC; Wang CQ
    Mol Cell Biochem; 2024 Nov; 479(11):3037-3047. PubMed ID: 38145448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
    Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer.
    Wang H; Wu D; Cai L; Li X; Zhang Z; Chen S
    J Cell Mol Med; 2020 Jun; 24(12):6869-6882. PubMed ID: 32394588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
    Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
    Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
    Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
    Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer Effects and Molecular Action of 7-α-Hydroxyfrullanolide in G2/M-Phase Arrest and Apoptosis in Triple Negative Breast Cancer Cells.
    Chimplee S; Roytrakul S; Sukrong S; Srisawat T; Graidist P; Kanokwiroon K
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.